According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
A number of other research analysts have also weighed in on the company. Wedbush reduced their target price on Aimmune Therapeutics from $80.00 to $76.00 and set an outperform rating for the company in a report on Tuesday, March 19th. BidaskClub lowered Aimmune Therapeutics from a sell rating to a strong sell rating in a report on Tuesday, April 23rd. Cantor Fitzgerald set a $45.00 target price on Aimmune Therapeutics and gave the company a buy rating in a report on Thursday, February 28th. Finally, Credit Suisse Group initiated coverage on Aimmune Therapeutics in a report on Tuesday, May 21st. They set an outperform rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $46.43.
Shares of AIMT opened at $19.62 on Monday. The business has a 50-day moving average price of $20.11. Aimmune Therapeutics has a fifty-two week low of $19.25 and a fifty-two week high of $36.12. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -5.35 and a beta of -0.12. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.19.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.07. As a group, sell-side analysts predict that Aimmune Therapeutics will post -3.77 EPS for the current year.
A number of hedge funds have recently bought and sold shares of AIMT. FMR LLC grew its stake in Aimmune Therapeutics by 30.3% in the first quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock worth $61,117,000 after purchasing an additional 635,362 shares during the period. Marshall Wace North America L.P. purchased a new stake in Aimmune Therapeutics in the first quarter worth $32,000. Knott David M grew its stake in Aimmune Therapeutics by 4.2% in the first quarter. Knott David M now owns 55,056 shares of the biotechnology company’s stock worth $1,231,000 after purchasing an additional 2,199 shares during the period. Botty Investors LLC purchased a new stake in Aimmune Therapeutics in the first quarter worth $2,505,000. Finally, Fiera Capital Corp grew its stake in Aimmune Therapeutics by 80.3% in the first quarter. Fiera Capital Corp now owns 160,572 shares of the biotechnology company’s stock worth $3,589,000 after purchasing an additional 71,519 shares during the period. 76.12% of the stock is owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: Net Margin – Understanding the Different Kinds of Profit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.